Belumosudil is a new medication approved by the FDA for treating cGVHD in patients who failed previous therapies. By inhibiting the ROCK2 enzyme, belumosudil reduces immune cell activation to decrease cytokines and chemokines that drive inflammation, fibrosis, and tissue damage. Clinical trials on patients with cGVHD demonstrated its efficacy with residual side effects such as hypertension, diarrhea, and fatigue. The medication is administered orally twice a day and requires further testing to determine its efficacy in other immune-mediated conditions.